Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Luster

Showing results (21-30 of 181) with videos related to

Pageof 19
Sort By:
Current Opinion in Oncology|December 2, 2016
Recent advances in nuclear medicine in endocrine oncologyMarkus Luster, Andreas Pfestroff, Frederik A Verburg
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2016
Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?Frederik A Verburg, Markus Luster, Luca Giovanella
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2004
Impact of 131I diagnostic activities on the biokinetics of thyroid remnantsMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Deutsche Medizinische Wochenschrift (1946)|July 8, 2020
[Follow-up of differentiated thyroid cancer]Friederike Eilsberger, Andreas Pfestroff, Damiano Librizzi, et al.
Deutsches Arzteblatt International|April 20, 2018
In ReplyDetlef K Bartsch, Markus Luster, Peter E Goretzki
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancerMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Thyroid : Official Journal of the American Thyroid Association|November 11, 2005
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administrationMarkus Luster, Ralph Felbinger, Markus Dietlein, et al.
Nuklearmedizin. Nuclear Medicine|October 13, 2021
[Therapy concepts for thyroid carcinoma]Friederike Eilsberger, Michael C Kreissl, Markus Luster, et al.
European Journal of Endocrinology|January 23, 2009
Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastasesFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Clinical Endocrinology|December 11, 2008
Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinomaFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Pageof 19

Showing results (21-30 of 181) with videos related to

Sort By:
Pageof 19
Current Opinion in Oncology|December 2, 2016
Recent advances in nuclear medicine in endocrine oncologyMarkus Luster, Andreas Pfestroff, Frederik A Verburg
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2016
Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?Frederik A Verburg, Markus Luster, Luca Giovanella
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2004
Impact of 131I diagnostic activities on the biokinetics of thyroid remnantsMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Deutsche Medizinische Wochenschrift (1946)|July 8, 2020
[Follow-up of differentiated thyroid cancer]Friederike Eilsberger, Andreas Pfestroff, Damiano Librizzi, et al.
Deutsches Arzteblatt International|April 20, 2018
In ReplyDetlef K Bartsch, Markus Luster, Peter E Goretzki
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancerMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Thyroid : Official Journal of the American Thyroid Association|November 11, 2005
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administrationMarkus Luster, Ralph Felbinger, Markus Dietlein, et al.
Nuklearmedizin. Nuclear Medicine|October 13, 2021
[Therapy concepts for thyroid carcinoma]Friederike Eilsberger, Michael C Kreissl, Markus Luster, et al.
European Journal of Endocrinology|January 23, 2009
Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastasesFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Clinical Endocrinology|December 11, 2008
Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinomaFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Pageof 19